N/A
N=34
Preoxygenation With Optiflow™ - the Effect of Speech on Lung Oxygenation.
Unrecognized Condition
Bottom Line
View on ClinicalTrials.gov: NCT03766646 ↗Enrolled (actual)
34
Serious AEs
—
Results posted
Oct 2020
Primary outcome: Primary: End Tidal Oxygen Fraction — 43.9; 81.9 percentage of End-Tidal Oxygen Fraction
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Optiflow (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Primary completion
- Nov 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY End Tidal Oxygen Fraction |
43.9; 81.9 | — |
Summary
If a patient speaks during the process of preoxygenation with high-flow nasal oxygen via the Optiflow™ system, is the efficacy reduced as measured by end-tidal lung oxygen content?
Eligibility Criteria
Inclusion Criteria
- BMI 18-35, ASA category 1 or 2
Exclusion Criteria
- Inability to read/ follow instructions, Heavily sedated
Data sourced from ClinicalTrials.gov (NCT03766646). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.